Iovance Biotherapeutics (IOVA) Panoramica del titolo
Iovance Biotherapeutics, Inc. è un'azienda biofarmaceutica in fase commerciale che sviluppa e commercializza terapie cellulari che utilizzano linfociti autologhi infiltranti il tumore per il trattamento del melanoma metastatico e di altri tumori solidi negli Stati Uniti e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 4/6 |
| Crescita futura | 5/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 3/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
IOVA Community Fair Values
Create NarrativeSee what 137 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Iovance Biotherapeutics, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$3.40 |
| Massimo di 52 settimane | US$5.63 |
| Minimo di 52 settimane | US$1.64 |
| Beta | 0.76 |
| Variazione di 1 mese | -0.87% |
| Variazione a 3 mesi | 30.27% |
| Variazione di 1 anno | -2.86% |
| Variazione a 3 anni | -50.37% |
| Variazione a 5 anni | -88.08% |
| Variazione dall'IPO | -34.72% |
Notizie e aggiornamenti recenti
IOVA: Q4 Margin Progress And Sarcoma Data Will Drive Upside Potential
Narrative Update: Iovance Biotherapeutics The analyst price target for Iovance Biotherapeutics has been lifted to $4. This reflects updated models that incorporate Q4 fundamentals, margin progress and expectations around Amtagvi and broader trial momentum, while still acknowledging areas of uncertainty highlighted by recent Street research.IOVA: Q4 Margin Gains And Sarcoma Data Are Expected To Drive Upside
The average analyst price target for Iovance Biotherapeutics has moved higher toward $4, supported by research citing improved Q4 fundamentals, margin progress, and early signs that initial launch issues may be easing. Analyst Commentary Recent research highlights a mix of optimism around product execution and margins alongside pockets of caution on valuation and growth risks.Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback
Apr 07
IOVA: Margin Progress And 2026 Sarcoma Data Outlook Will Support Higher Future P/E
The analyst fair value estimate for Iovance Biotherapeutics has been adjusted from $17.00 to $16.00, reflecting updated views on revenue growth, margins, and future P/E assumptions as analysts respond to recent price target moves and Q4 results across the Street. Analyst Commentary Street research around the latest quarter points to a generally constructive shift in sentiment, with several bullish analysts lifting price targets and, in one case, upgrading the rating on Iovance Biotherapeutics.Recent updates
IOVA: Q4 Margin Progress And Sarcoma Data Will Drive Upside Potential
Narrative Update: Iovance Biotherapeutics The analyst price target for Iovance Biotherapeutics has been lifted to $4. This reflects updated models that incorporate Q4 fundamentals, margin progress and expectations around Amtagvi and broader trial momentum, while still acknowledging areas of uncertainty highlighted by recent Street research.IOVA: Q4 Margin Gains And Sarcoma Data Are Expected To Drive Upside
The average analyst price target for Iovance Biotherapeutics has moved higher toward $4, supported by research citing improved Q4 fundamentals, margin progress, and early signs that initial launch issues may be easing. Analyst Commentary Recent research highlights a mix of optimism around product execution and margins alongside pockets of caution on valuation and growth risks.Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback
Apr 07IOVA: Margin Progress And 2026 Sarcoma Data Outlook Will Support Higher Future P/E
The analyst fair value estimate for Iovance Biotherapeutics has been adjusted from $17.00 to $16.00, reflecting updated views on revenue growth, margins, and future P/E assumptions as analysts respond to recent price target moves and Q4 results across the Street. Analyst Commentary Street research around the latest quarter points to a generally constructive shift in sentiment, with several bullish analysts lifting price targets and, in one case, upgrading the rating on Iovance Biotherapeutics.IOVA: Fair Outlook Balances Q4 Progress With 2026 Clinical And Launch Risks
The analyst price target for Iovance Biotherapeutics has shifted from $2 to $4 as analysts point to stronger Q4 fundamentals, improving margins, ongoing manufacturing progress, and early signs that some initial launch issues for Amtagvi may be easing, even while longer term revenue acceleration remains uncertain. Analyst Commentary Recent Street research around Iovance Biotherapeutics reflects a mixed setup, with price target changes clustered across a wide range and ratings spanning Neutral to Buy.IOVA: Elevated Future P/E Will Likely Clash With 2026 Clinical Data Risks
Analysts have lifted their price targets on Iovance Biotherapeutics from a range starting at $3 to as high as $16, citing Q4 revenue momentum, improving gross margins and manufacturing efficiency, and expectations for more clinical data in 2026. Analyst Commentary Recent research highlights a split in how Wall Street views Iovance Biotherapeutics, with some firms lifting price targets on the back of Q4 execution and others trimming expectations while still acknowledging operational progress.IOVA: Elevated Future P/E Will Likely Expose Execution Risk
Analysts have raised their price target on Iovance Biotherapeutics by $0.50, citing updated assumptions around fair value, growth, margins, and future P/E that reflect recent Street research. Analyst Commentary Recent Street research on Iovance Biotherapeutics has highlighted a mix of optimism and caution around the updated price target, with some readers likely to focus less on the small US$0.50 change and more on what it implies about risk and execution.IOVA: Reaffirmed 2025 Revenue Outlook Will Support A Higher Future P/E
Analysts have trimmed their fair value estimate for Iovance Biotherapeutics from US$20.00 to US$17.00, citing updated assumptions that include a slightly higher discount rate, a lower projected revenue growth rate, a modestly higher profit margin, and a reduced future P/E multiple. What's in the News Iovance Biotherapeutics reaffirmed its full year 2025 revenue guidance, keeping the expected range at US$250 million to US$300 million for the first full calendar year of Amtagvi sales (Key Developments).
IOVA: Lung Cancer Trial Progress Will Drive Bullish Repricing Ahead
Analysts have kept their price target for Iovance Biotherapeutics steady at US$8.35, citing only minor tweaks to inputs such as the discount rate and long term P/E assumptions rather than any fundamental shift in their outlook. What's in the News Iovance Biotherapeutics reaffirmed its full year 2025 revenue guidance, keeping the range at US$250 million to US$300 million for the first full calendar year of Amtagvi sales (Company guidance).IOVA: Future Lung Cancer Data Will Drive Renewed Bullish Momentum
Analysts have modestly increased their price target on Iovance Biotherapeutics by 0.10 dollars to reflect slightly lower perceived risk, as seen in a reduced discount rate, while maintaining robust long term revenue growth and profit margin expectations alongside a marginally higher future price to earnings multiple. What's in the News Iovance reaffirmed its full year 2025 revenue guidance of 250 to 300 million dollars for the first full calendar year of Amtagvi sales, signaling confidence in launch momentum (company guidance) Interim data from the registrational Phase 2 IOV-LUN-202 trial showed a 25.6 percent objective response rate for lifileucel monotherapy in previously treated advanced nonsquamous NSCLC without actionable mutations, including 2 complete and 7 partial responses and a 71.8 percent disease control rate (company trial update) The median duration of response for lifileucel in IOV-LUN-202 has not yet been reached after a median follow up of 25.4 months, indicating durable benefit among responding NSCLC patients (company trial update) Valuation Changes Fair Value: increased slightly from 8.25 dollars to 8.35 dollars, reflecting a modest uplift in the intrinsic valuation estimate.IOVA: Future Lung Cancer Data Will Drive Renewed Bullish Momentum
Analysts have modestly reduced their price target on Iovance Biotherapeutics to reflect slightly slower projected revenue growth, a meaningfully lower long term profit margin outlook, and a higher assumed future price to earnings multiple, while leaving the estimated fair value effectively unchanged at about 8.25 dollars per share. What's in the News Iovance Biotherapeutics reaffirmed its full year 2025 revenue guidance, targeting between 250 million dollars and 300 million dollars in the first full calendar year of Amtagvi sales (company guidance).IOVA: Future Phase 2 Data Will Drive Renewed Bullish Momentum
Analysts have raised their price target for Iovance Biotherapeutics from $7.75 to $8.25 per share, citing updated financial metrics and modestly adjusted long-term growth assumptions. What's in the News Iovance Biotherapeutics reaffirmed its revenue guidance for the full year 2025, projecting $250 to $300 million in the first full calendar year of Amtagvi sales.IOVA: Future Profitability Outlook Will Drive Renewed Investor Interest
Analysts have adjusted their price target for Iovance Biotherapeutics from $8.00 to $7.75. This change reflects updated views on the company's growth trajectory and profitability outlook.Here's What Analysts Are Forecasting For Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) After Its Third-Quarter Results
Nov 08
IOVA: Advanced Melanoma Approval and Equity Raise Will Drive Upside Potential
Analysts have lowered their price target for Iovance Biotherapeutics from $9.10 to $8.00. They cite updated expectations for slower revenue growth, compressed profit margins, and a higher required rate of return.Oncology Expansion And Global Approvals Will Unlock Future Markets
The consensus analyst price target for Iovance Biotherapeutics has been revised downward to $9.10 as slower-than-expected Amtagvi commercial adoption and logistical challenges outweigh positive early clinical response data. Analyst Commentary Bearish analysts cite a slower-than-expected commercial launch for Amtagvi in second-line melanoma, driving down sentiment and price targets.Oncology Expansion And Global Approvals Will Unlock Future Markets
The decrease in Iovance Biotherapeutics' consensus price target is primarily driven by a reduction in expected annual revenue growth from 49.7% to 45.5%, resulting in a lowered fair value estimate from $10.00 to $9.10. What's in the News Five-year results from the Phase 2 C-144-01 trial showed Amtagvi (lifileucel) produced a median OS of 13.9 months and a 31.4% objective response rate in advanced melanoma patients; 19.7% survived at five years with durable responses and no new safety concerns.Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Fly 26% But Investors Aren't Buying For Growth
Jul 22Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) 46% Dip In Price Shows Sentiment Is Matching Revenues
May 16News Flash: 12 Analysts Think Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Earnings Are Under Threat
May 13
US Launch And Global Expansion Will Create New Opportunities
The U.S. launch of Amtagvi and international expansion could drive significant revenue and market growth, enhancing revenue streams and market share.Iovance Biotherapeutics: Only For The Brave
Apr 22Iovance: The Company Makes It Hard To Estimate Revenue Growth
Mar 18Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported Earnings, And Analysts Cut Their Target Price
Mar 02Iovance's Q4: Execution Risks Mount As Infusion Growth Slows (Rating Downgrade)
Feb 28Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) May Have Run Too Fast Too Soon With Recent 25% Price Plummet
Jan 11Iovance Biotherapeutics: Amtagvi Launch Growing, But Stock Isn't
Dec 17Iovance Biotherapeutics Q3: A Beat, But A Selloff - Now A Buy Opportunity
Nov 11Iovance Biotherapeutics: Moving To The Next Phase
Oct 03Iovance Therapeutics: Historic Product, Tough Commercial Outlook
Sep 06Earnings Update: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported And Analysts Are Boosting Their Estimates
Aug 11Iovance's Tumor-Fighting TILs Are Just Warming Up (Rating Upgrade)
Aug 11Iovance Biotherapeutics: Amtagvi Launch Continues Upward
Jun 26Iovance Q1 Earnings Review: Not Enough Data To Draw Conclusions On Amtagvi
May 10Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results
Apr 09Iovance Biotherapeutics: Initial Amtagvi Launch In Focus
Mar 25Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In Melanoma
Feb 20Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date
Jan 19Rendimenti per gli azionisti
| IOVA | US Biotechs | US Mercato | |
|---|---|---|---|
| 7D | -1.2% | -2.4% | 0.8% |
| 1Y | -2.9% | 27.4% | 27.8% |
Ritorno vs Industria: IOVA ha avuto una performance inferiore rispetto al US Biotechs che ha registrato un rendimento 27.4 % nell'ultimo anno.
Rendimento vs Mercato: IOVA ha avuto una performance inferiore al mercato US che ha registrato un rendimento 27.8 % nell'ultimo anno.
Volatilità dei prezzi
| IOVA volatility | |
|---|---|
| IOVA Average Weekly Movement | 14.4% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di IOVA è stato volatile rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 14% ) di IOVA è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2007 | 975 | Frederick Vogt | www.iovance.com |
Iovance Biotherapeutics, Inc. è una società biofarmaceutica in fase di sviluppo commerciale che sviluppa e commercializza terapie cellulari che utilizzano linfociti autologhi infiltranti il tumore per il trattamento del melanoma metastatico e di altri tumori solidi negli Stati Uniti e a livello internazionale. L'azienda offre Amtagvi, una terapia individualizzata a base di cellule T per il trattamento di tumori solidi e per il trattamento di pazienti adulti con melanoma avanzato, non resecabile o metastatico precedentemente trattato; e Proleukin, un prodotto a base di interleuchina-2 per il trattamento di pazienti con melanoma metastatico e carcinoma a cellule renali metastatico. Sviluppa inoltre lifileucel per il trattamento del melanoma, del carcinoma della cervice uterina, del carcinoma polmonare non a piccole cellule (NSCLC), del carcinoma endometriale e del carcinoma a cellule squamose della testa e del collo (HNSCC); LN-145-S1 per il trattamento del melanoma e dell'HNSCC; LN-145 Gen 3 e core biopsy per il trattamento dell'NSCLC; LN-145 Gen 3 per il trattamento del melanoma e dell'HNSCC; IOV-2001 per il trattamento della leucemia linfocitica cronica e del linfoma piccolo linfocitico; IOV-4001 per il trattamento del melanoma e dell'NSCLC; e IOV-3001 per l'uso nel regime terapeutico TIL.
Iovance Biotherapeutics, Inc. Riepilogo dei fondamenti
| IOVA statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$1.40b |
| Utili (TTM) | -US$390.98m |
| Ricavi(TTM) | US$263.50m |
IOVA è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| IOVA Conto economico (TTM) | |
|---|---|
| Ricavi | US$263.50m |
| Costo del fatturato | US$173.18m |
| Profitto lordo | US$90.32m |
| Altre spese | US$481.30m |
| Utili | -US$390.98m |
Ultimi utili riportati
Dec 31, 2025
Prossima data di guadagno
May 07, 2026
| Utile per azione (EPS) | -0.95 |
| Margine lordo | 34.28% |
| Margine di profitto netto | -148.38% |
| Rapporto debito/patrimonio netto | 0.1% |
Come si è comportato IOVA nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/03 11:10 |
| Prezzo dell'azione a fine giornata | 2026/05/01 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Iovance Biotherapeutics, Inc. è coperta da 21 analisti. 10 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Colleen Kusy | Baird |
| Madhu Kumar | Baird |
| Peter Lawson | Barclays |